+

WO1988009181A3 - Anticorps monoclonaux neutralisant le hiv-1 - Google Patents

Anticorps monoclonaux neutralisant le hiv-1 Download PDF

Info

Publication number
WO1988009181A3
WO1988009181A3 PCT/US1988/001797 US8801797W WO8809181A3 WO 1988009181 A3 WO1988009181 A3 WO 1988009181A3 US 8801797 W US8801797 W US 8801797W WO 8809181 A3 WO8809181 A3 WO 8809181A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
hiv
monoclonal antibodies
neutralizing hiv
antibodies neutralizing
Prior art date
Application number
PCT/US1988/001797
Other languages
English (en)
Other versions
WO1988009181A2 (fr
Inventor
Tse Wen Chang
Sek C Fung
Cecily Rou-Yun Sun
Bill Nai-Chau Sun
Nancy T Chang
Ruey Shyan Liou
Edward M Rosen
Original Assignee
Tanox Biosystems Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Biosystems Inc, Baylor College Medicine filed Critical Tanox Biosystems Inc
Priority to EP88906589A priority Critical patent/EP0366718B1/fr
Priority to DE3853779T priority patent/DE3853779T2/de
Publication of WO1988009181A2 publication Critical patent/WO1988009181A2/fr
Publication of WO1988009181A3 publication Critical patent/WO1988009181A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Sont décrits des anticorps monoclonaux qui se lient à la protéine gp 120 sur l'enveloppe du HIV-1. Ces anticorps neutralisent le HIV-1. Ils inhibent le rythme d'infection de cellules T, et inhibent également la formation de syncytium. En outre, les anticorps sont spécifiques à des groupes, ils neutralisent différentes souches et isolats de HIV-1. Ces anticorps ont diverses utilisations, y compris le traitement et la prévention du SIDA et de l'ARC (complexe relatif au SIDA). Sont également décrits des anticorps de neutralisation virale chimériques, y compris des anticorps chimériques neutralisant le HIV.
PCT/US1988/001797 1987-05-29 1988-05-27 Anticorps monoclonaux neutralisant le hiv-1 WO1988009181A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP88906589A EP0366718B1 (fr) 1987-05-29 1988-05-27 Anticorps monoclonaux neutralisant le hiv-1
DE3853779T DE3853779T2 (de) 1987-05-29 1988-05-27 Hiv-1 neutralisierende monoklonale antikörper.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US5744587A 1987-05-29 1987-05-29
US057,445 1987-05-29
US13786187A 1987-12-24 1987-12-24
US137,861 1987-12-24
US19776688A 1988-05-23 1988-05-23
US197,766 1988-05-23

Publications (2)

Publication Number Publication Date
WO1988009181A2 WO1988009181A2 (fr) 1988-12-01
WO1988009181A3 true WO1988009181A3 (fr) 1989-02-09

Family

ID=27369250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/001797 WO1988009181A2 (fr) 1987-05-29 1988-05-27 Anticorps monoclonaux neutralisant le hiv-1

Country Status (6)

Country Link
EP (1) EP0366718B1 (fr)
JP (1) JP2520464B2 (fr)
AT (1) ATE122237T1 (fr)
CA (1) CA1339857C (fr)
DE (1) DE3853779T2 (fr)
WO (1) WO1988009181A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591829A (en) * 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
US5854400A (en) * 1987-05-29 1998-12-29 Tanox, Inc. Monoclonal antibodies which neutralize HIV-1 infection
AU621097B2 (en) * 1988-01-26 1992-03-05 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A synthetic antigen evoking anti-hiv response
JP2646007B2 (ja) * 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
CA1341285C (fr) * 1988-02-12 2001-08-14 Chang Yi Wang Peptides synthetiques servant a la detection d'anticorps de la proteine de surface gp120 du virus hiv, destines au diagnostic du sida, ainsi que d'etats pre-sidatiques, ou aux fins de vaccins
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
EP0339504A3 (fr) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
ATE140233T1 (de) * 1988-05-13 1996-07-15 University Patents Inc Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
AU640619B2 (en) * 1988-10-03 1993-09-02 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
EP0365209A3 (fr) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Séquence aminoacidique de l'anti-leu 3a
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
ATE148918T1 (de) * 1989-04-25 1997-02-15 Tanox Biosystems Inc Für die co4-bindende domäne von hiv spezifische antikörper
JP2782232B2 (ja) * 1989-05-29 1998-07-30 日東電工株式会社 プロテアーゼ阻害剤
EP0478689A4 (en) * 1989-06-05 1993-06-16 Charles F. Scott Jr. Human monoclonal antibodies to hiv-1 mn? gp 120
AU632843B2 (en) * 1989-08-10 1993-01-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
CA1339415C (fr) * 1989-08-24 1997-09-02 Milton David Goldenberg Detection et traitement des infections au moyen d'immunoconjugues
KR910009285A (ko) * 1989-11-13 1991-06-28 원본미기재 Hiv 항원에 특이적인 키메라형 생쥐-인간항체
WO1991007493A1 (fr) * 1989-11-13 1991-05-30 Xoma Corporation Anticorps murins humains chimeriques a specificite aux antigenes du vih
DE69028713T3 (de) * 1989-12-27 2004-05-13 Centocor, Inc. Schimäre immunoglobuline für cd4-rezeptoren
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
SE9000333D0 (sv) * 1990-01-31 1990-01-31 Britta Wahren Monoklonal antikropp
US5914109A (en) * 1990-06-15 1999-06-22 New York University Heterohybridomas producing human monoclonal antibodies to HIV-1
US5712373A (en) * 1990-07-02 1998-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute HIV monoclonal antibody specific for the HTLV-IIImn gp120 envelope glycoprotein
JP2989862B2 (ja) * 1990-07-02 1999-12-13 財団法人化学及血清療法研究所 モノクローナル抗体
WO1992005799A1 (fr) * 1990-09-28 1992-04-16 Hospital For Joint Diseases Procede inhibant l'action infectieuse du virus de l'immunodeficience humaine
HUT66445A (en) * 1990-10-26 1994-11-28 New York Health Res Inst Monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
AU8900691A (en) * 1990-11-19 1992-06-11 Queen's University At Kingston Hiv marker/aids vaccine
US5558865A (en) * 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
ATE173024T1 (de) * 1991-08-22 1998-11-15 Nissin Food Products Ltd In der therapie von einer hiv-1-infektion verwendbare monoklonale antikörper
JPH0748276A (ja) * 1992-03-26 1995-02-21 Inmeru:Kk Ｈｉｖ感染症予防ワクチンおよびその製造法
NZ251582A (en) * 1992-04-01 1997-07-27 Merck & Co Inc Recombinant human anti-hiv antibodies, methods for their cloning and expression and pharmaceutical compositions thereof
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
WO1994020632A1 (fr) * 1993-03-11 1994-09-15 Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute Anticorps monoclonal dirige contre le vih
US5618922A (en) 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
WO1998043995A1 (fr) * 1997-03-28 1998-10-08 Seikagaku Corporation Nouveaux complexes anti-vih et compositions medicamenteuses
DE19809785C2 (de) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmunpharmakon zur Behandlung der HIV-1-Infektion
EP1006191A3 (fr) 1998-12-03 2002-02-06 Canon Kabushiki Kaisha ADN encodant la monooxygenase du toluène, méthode pour la dégradation d' hydrocarbures aliphatiques chlorés et composés aromatiques ainsi que méthode de la décontamination de l'environnement
WO2007134037A2 (fr) * 2006-05-15 2007-11-22 Immunomedics, Inc. Procédés et compositions de traitement d'infections par le virus de l'immunodéficience humaine avec des anticorps ou des fragments d'anticorps conjugués
US9687547B2 (en) 2015-05-28 2017-06-27 Immunomedics, Inc. T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002383A1 (fr) * 1984-10-18 1986-04-24 Institut Pasteur Antigenes d'enveloppe du virus des lymphadenopathies et leurs applications
EP0214709A2 (fr) * 1985-09-11 1987-03-18 United Biomedical Inc. Peptide synthétique et procédé pour son utilisation dans la détection d'anticorps de HTLV-III, le diagnostic de SIDA et pré-SIDA et comme vaccin
WO1987002775A1 (fr) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Peptides synthetiques et leur utilisation pour le diagnostic et la vaccination contre le sida et son complexe associe
DE3727703A1 (de) * 1986-08-20 1988-05-05 Genetic Systems Corp Monoklonale antikoerper und peptide, welche zur behandlung und diagnose von hiv-infektionen brauchbar sind

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
FR2571968B1 (fr) * 1984-10-18 1989-03-17 Pasteur Institut Virus purifie des lymphadenopathies et du syndrome d'immuno-depression acquise et antigenes d'enveloppe de ce virus, procede d'obtention de ce virus et de ces antigenes d'enveloppe de ce virus, applications de ce virus ou de ces antigenes a la preparation de compositions immunogenes ou pour le diagnostic des susdites affections.
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002383A1 (fr) * 1984-10-18 1986-04-24 Institut Pasteur Antigenes d'enveloppe du virus des lymphadenopathies et leurs applications
EP0214709A2 (fr) * 1985-09-11 1987-03-18 United Biomedical Inc. Peptide synthétique et procédé pour son utilisation dans la détection d'anticorps de HTLV-III, le diagnostic de SIDA et pré-SIDA et comme vaccin
WO1987002775A1 (fr) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Peptides synthetiques et leur utilisation pour le diagnostic et la vaccination contre le sida et son complexe associe
DE3727703A1 (de) * 1986-08-20 1988-05-05 Genetic Systems Corp Monoklonale antikoerper und peptide, welche zur behandlung und diagnose von hiv-infektionen brauchbar sind

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, Vol. 107, No. 3, 20 July 1987, (Columbus, Ohio, US), Ho David et al.: "Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins", page 460, abstract 21646h, & J. Virol. 1987, 61(6), pages 2024-8 *
European Journal Immunology, 1986, Vol. 16, T. C. Chanh et al.: "Human immunodeficiency virus gp 120 glycoprotein detected by a monoclonal antibody to a synthetic peptide", pages 1465-1468 *
Nature, Vol. 324, 11 December 1986, R.A. Weiss et al.: "Variable and conserved neutralization antigens of human immunodeficiency virus" pages 572-75. *
Proc. Natl. Acad. Sci. USA, Vol. 84, May 1987, P.H. Naylor et al.: "Human immunodeficiency virus contains an epitope immunoreactive with thymosin Alpha¹ and the 30-amino acid synthetic p17 group-specific antigen peptide hgp-30" pages 2951 and 2954. *
Science, Vol. 234, 12 December 1986, S.D. Putney et al.: "HTLV-III/LAV-Neutralizing Antibodies to an E.coli-Produced Fragment of the Virus Envelope", pages 1392-95. *
The Journal of Biological Chemistry, Vol. 262, No. 12, 25 April 1987, R.C. Cannedy et al.: "Use of a Resin-bound Synthetic peptide for Identifying a Neutralizing Antigenic Determinant Associated with the Human Immunodeficiency Virus Envelope" pages 5769-5774. *

Also Published As

Publication number Publication date
DE3853779T2 (de) 1995-09-07
JPH03504556A (ja) 1991-10-09
WO1988009181A2 (fr) 1988-12-01
DE3853779D1 (de) 1995-06-14
JP2520464B2 (ja) 1996-07-31
EP0366718B1 (fr) 1995-05-10
ATE122237T1 (de) 1995-05-15
EP0366718A1 (fr) 1990-05-09
CA1339857C (fr) 1998-05-05

Similar Documents

Publication Publication Date Title
WO1988009181A3 (fr) Anticorps monoclonaux neutralisant le hiv-1
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
DE3850542T2 (de) Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
EP0675904A4 (fr) Anticorps monoclonaux neutralisateurs humains contre le virus de l'immunodeficience humaine.
EP0651818A4 (fr) Peptides immunogenes, anticorps et utilisations de ceux-ci en rapport avec la liaison du recepteur de molecules cd4.
AU589732B2 (en) Process for the preparation of 2-oxo-1,3-dioxolanes
ATE144793T1 (de) Bispezifische reagenzien für die aids-therapie
CA2096159A1 (fr) Peptides induisant des anticorps qui neutralisent les isolats de vih-1 divergents sur le plan genetique
CA2143163A1 (fr) Peptides derives d'un retrovirus du groupe vih et leur utilisation
IL118626A0 (en) Anti HBV antibody
CA2130360A1 (fr) Derives de l'acide sulfonique pour le traitement des maladies virales
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
CA2170034A1 (fr) Anticorps humanise recombinant, anti-virus de l'immunodeficience humaine
CA2153165A1 (fr) Anticorps anti-vih recombinant et methode de preparation
WO1997046697A3 (fr) Anticorps diriges contre un complexe de cd4 et d'un domaine de recepteurs des chemokines, et leur utilisation pour lutter contre les infections a vih
EP0306219A3 (fr) Protéines et peptides du HIV pour le diagnostic, la prophylaxie et la thérapie du SIDA
CA2169603A1 (fr) Retrovirus du groupe vih et son utilisation
ES468363A1 (es) Proceso para la fabricacion de un preparado destinado al tra-tamiento de herpes-zoster.
EP0344006A3 (fr) Peptides bloquant la liaison de HIV-1 vers CD4 du récepteur de protéine
WO1993001820A3 (fr) Inhibition de l'infection hiv a mediation par la proteine non-cd4
AU8010791A (en) Hiv monoclonal antibody
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
ES8206473A1 (es) Procedimiento para la preparacion de derivados de prostaci- clina
EP0323157A3 (fr) Composés antiviraux et méthodes
AP9600896A0 (en) Anti-HIV triple combination.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988906589

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988906589

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1988906589

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载